MYLAN-EZETIMIBE ezetimibe 10 mg tablets blister pack

Država: Australija

Jezik: engleski

Izvor: Department of Health (Therapeutic Goods Administration)

Aktivni sastojci:

ezetimibe, Quantity: 10 mg

Dostupno od:

Alphapharm Pty Ltd

Farmaceutski oblik:

Tablet

Sastav:

Excipient Ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium lauryl sulfate; hypromellose; croscarmellose sodium; crospovidone

Administracija rute:

Oral

Jedinice u paketu:

30, 10, 5

Tip recepta:

(S4) Prescription Only Medicine

Terapijske indikacije:

Primary Hypercholesterolaemia,Ezetimibe administered alone, or with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,Homozygous Familial Hypercholesterolaemia (HoFH),Ezetimibe, administered with a statin, is indicated for patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Proizvod sažetak:

Visual Identification: White to off white capsule shaped, bevelled edge tablet debossed with M on one side of the tablet and EE1 on the other side.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Status autorizacije:

Registered

Datum autorizacije:

2021-01-11